Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Variables in ICI Toxicity
NCT05429866Phase 2Unknown
- Sponsor
- Institut Jules Bordet
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial in solid tumor (3 arms), sponsored by Institut Jules Bordet. Primary endpoints: Modification(s) in the immune blood markers of treated subjects on treatment (Early), Modification(s) in the immune blood markers of treated subjects on treatment (Midtime) and 3 more. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05429866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429866.